Log in
Enquire now
‌

US Patent 11840559 Glucagon-receptor selective polypeptides and methods of use thereof

Patent 11840559 was granted and assigned to i2O Therapeutics, Inc. on December, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc.
0
Current Assignee
i2O Therapeutics, Inc.
i2O Therapeutics, Inc.
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
118405590
Patent Inventor Names
Andrew Young0
Ved P. Srivastava0
Robert Neil Hunter, III0
William Blackwell0
Steven Thomas Dock0
Mark A. Paulik0
Date of Patent
December 12, 2023
0
Patent Application Number
175385070
Date Filed
November 30, 2021
0
Patent Citations
‌
US Patent 6875748 Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
0
‌
US Patent 6887470 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
0
‌
US Patent 6887849 Long lasting synthetic glucagon-like peptide {GLP-1}
0
‌
US Patent 6899887 Osmotic delivery system with membrane plug retention mechanism
0
‌
US Patent 6899898 Induced phase transition method for the production of microparticles containing hydrophobic active agents
0
‌
US Patent 6902744 Exendin agonist formulations and methods of administration thereof
0
‌
US Patent 6903186 Analogues of GLP-1
0
‌
US Patent 6913767 Compositions for microencapsulation of antigens for use as vaccines
0
...
Patent Primary Examiner
‌
Lianko G Garyu
0
CPC Code
‌
A61K 38/26
0
‌
C07K 14/605
0
Patent abstract

This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11840559 Glucagon-receptor selective polypeptides and methods of use thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.